Grants Review and Awards
Dr Francisco J. Rodríguez
Dr Rodríguez is the Chair of the Fundación Oftalmológica Nacional and Chairman of the Department of Ophthalmology at Universidad del Rosario School of Medicine in Bogotá, Colombia. He received his medical degree from the Universidad del Rosario School of Medicine in 1986, and carried out his ophthalmology residency at the Fundación Oftalmológica Nacional. Dr Rodríguez then completed a vitreoretinal surgical fellowship at the Jules Stein Eye Institute of the University of California, Los Angeles, USA; a medical retina fellowship at the Manhattan Eye, Ear and Throat Hospital in New York, USA; and an electrophysiology/hereditary retinal diseases fellowship at Bascom Palmer Eye Institute of the University of Miami Leonard M. Miller School of Medicine, Florida.
Dr Rodríguez has participated as a principal investigator in clinical trials, and he has received several awards, including the National Academy of Medicine award in 1997. He has produced more than 75 publications in national and international peer-reviewed journals and has also authored several chapters in retina textbooks. His research interests include diabetic retinopathy, age related macular degeneration, inflammatory diseases of the retina and choroid, retinal vascular diseases, retinal imaging, retinal detachment and macular surgery.
Dr Rodríguez's institution: www.fundonal.org
Dr Jennifer Arnold
Dr Arnold is a partner at Marsden Eye Specialists in New South Wales, Australia. She specializes in retinal and macular diseases, as well as cataracts and all aspects of general ophthalmology.
As well as performing clinical duties, Dr Arnold coordinates a research team of ophthalmologists, orthoptists, and registered nurses that conducts numerous ongoing international and local clinical trials. Her main research focus is the development of new treatments for age-related macular degeneration (AMD), diabetic macular oedema, and retinal vein occlusion. Indeed, Dr Arnold was involved in the revolutionary work carried out in recent years to improve the diagnosis and management of AMD.
Dr Arnold has numerous publications and is a member of the Macula Society. In 2012, she became the co-chair of the GRAC for Bayer’s GOAP, alongside Professor Quan Dong Nguyen.
Dr Arnold is co-chair of the GRAC, alongside Professor Quan Dong Nguyen.
Dr Patricia A. D’Amore
Dr D’Amore is the Charles L. Schepens Professor of Ophthalmology, Professor of Pathology, and Vice-Chair of Basic Research at Harvard Medical School in Boston, Massachusetts, USA; Director of Research, Senior Scientist, and Ankeny Scholar of Retinal Molecular Biology at the Schepens Eye Research Institute at Massachusetts Eye and Ear in Boston; and Director of the Howe Laboratory and Associate Chief of Basic and Translational Research at Massachusetts Eye and Ear. Her research focuses on understanding the mechanism of vascular growth, development and pathology, and pericyte-endothelial cell interactions as well as the pathogenesis of dry age-related macular degeneration.
After receiving a bachelor degree from Regis College in Weston, Massachusetts, Dr D’Amore obtained a PhD in Biology from Boston University, followed by a postdoctoral fellowship in biological chemistry and ophthalmology at Johns Hopkins University School of Medicine, Baltimore, Maryland. She then received an MBA in Finance from Northeastern University in Boston, and was selected as a Fellow of the Association for Research in Vision and Ophthalmology (FARVO) in 2009 and a member of the American Academy of Arts and Sciences in 2018.
Dr D’Amore has over 200 publications to her credit, appearing in journals such as Nature Medicine, Journal of Clinical Investigation, Development, and the Journal of Cell Biology. In addition to her scientific achievements, Dr D’Amore has won numerous awards for her role as a mentor and teacher, having trained over 70 undergraduate, graduate and medical students, and postdoctoral fellows.
Dr Peter Kertes
Dr Peter Kertes majored in molecular biology at Princeton University, NJ, USA, as an undergraduate and went to McGill University in Montreal, QC, Canada, for medical school. He then did a residency in ophthalmology at the University of Ottawa, and undertook a 2-year vitreoretinal surgical fellowship with Dr Gholam Peyman at Louisiana State University in New Orleans.
Dr Kertes was in practice in Ottawa from 1997 and moved to the Sunnybrook Health Sciences Centre in Toronto, ON, Canada, in 2003 where he is currently a vitreoretinal surgeon and the Ophthalmologist-in-Chief of the John and Liz Tory Eye Centre at Sunnybrook. Furthermore, Dr Kertes is a Professor of Ophthalmology and Vision Sciences at the University of Toronto and is on staff at the Hospital for Sick Children in Toronto.
Dr Kertes has an interest in clinical epidemiology and evidence-based medicine, publishing three books on the major clinical trials in ophthalmology, which are a staple of every resident’s library. He served as one of the Editors-in-Chief of the journal Evidence-based Ophthalmology, and has authored many textbook chapters and almost 80 peer-reviewed publications.
Dr Kertes has a special interest in international ophthalmology and has participated in 23 volunteer projects throughout the developing world, many of them focused on retinopathy of prematurity and paediatric retina.
Dr William Li
Dr Li received his bachelor’s degree with honours in biochemistry from Harvard College in Cambridge, Massachusetts, USA, and his medical degree from the University of Pittsburgh School of Medicine, Pennsylvania. He completed his residency training and clinical fellowship in General Internal Medicine at the Massachusetts General Hospital in Boston.
Dr Li is President, Medical Director, and co-founder of the Angiogenesis Foundation, a non-profit organization that is reconceptualizing global disease fighting.
A protégé of medical pioneer Dr Judah Folkman, Dr Li has been engaged in research focused on angiogenesis and its practical applications in ophthalmology, cancer, wound and tissue repair, cardiovascular diseases, and other pathologies. A major part of Dr Li’s work focuses on translating science to practical interventions that improve health outcomes for individuals and populations using angiogenesis-based therapies. Dr Li has testified before congressional and other governmental audiences on the impact of angiogenesis in healthcare, and he works internationally with medical, scientific, bio-pharmaceutical, device, payor, and health policy audiences. His non-profit work has been cited by The New York Times, Fortune, and CNN. He has also been a speaker at a TED conference, and is a member of the Clinton Global Initiative.
Dr Li has served on faculties at Harvard Medical School in Boston, Tufts University in Medford, Massachusetts, and the Geisel School of Medicine at Dartmouth, New Hampshire. He has numerous papers in Science, The New England Journal of Medicine, The Lancet, and other leading peer-reviewed medical journals.
Mr Philip Hykin
Mr Hykin was appointed Consultant Ophthalmologist to the Medical Retina Service at Moorfields Eye Hospital, London, UK, in 1996 and was Director of the Medical Retina Service from 2003 to 2008. His training in retinal ophthalmology began at Moorfields and, after a period of research at University College London Institute of Ophthalmology, he completed a fellowship at Wills Eye Hospital, Philadelphia, Pennsylvania, USA. He currently holds medical retina clinics, concentrating on patients with retinovascular disease and AMD. Special interests include the pathogenesis of DME, idiopathic polypoidal choroidal vasculopathy, neovascular AMD, and new therapies for diabetic maculopathy and proliferative retinopathy.
Mr Hykin has given numerous invited lectures in the UK and abroad, and is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology, and the Macula Society. He has over 90 publications in peer-reviewed journals and has contributed to numerous book chapters. He was UK chief investigator for trials of sodium pegaptanib and other anti-VEGF agents in neovascular AMD, principal investigator for trials of ruboxistaurin in DME, posurdex in central and branch retinal vein occlusion, intravitreal triamcinolone in DME, and bevacizumab in diabetic maculopathy. Recent UK NIHR funded projects include the use of anti-VEGF therapy in proliferative diabetic retinopathy and central retinal vein occlusion.
Professor Calvin C. P. Pang
Professor Pang is S.H. Ho Professor of Visual Sciences and Professor of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong (CUHK), China, and is Director of the Shantou University / CUHK Joint Shantou International Eye Center. He was former Chairman of the Department of Ophthalmology and Visual Sciences at CUHK.
Professor Pang received a BSc in Biochemistry in 1978 from the University of London, UK. He then completed a DPhil research program at the University of Oxford, UK, on an E.P. Abraham Scholarship, followed by 2 years’ postdoctoral research in Oxford. In 2016 Prof Pang received the China State Scientific and Technological Progress Award (SSTPA) second-class award. He was bestowed the Special Achievement Award of Chinese Ophthalmological Society 2017 and Senior Achievement Award, Asia Pacific Academy of Ophthalmology 2018. He is reviewer or academic assessor for the Wellcome Trust (UK), National Eye Institute (USA), Association for Research in Vision and Ophthalmology (USA), National Medical Research Council (Singapore), National Health & Medical Research Council (Australia), National Science Foundation China, Chiangjiang Scholars Program China, and other funding organisations. He is also academic reviewer, external examiner and honorary or visiting professor of more than 60 clinical, research and tertiary academic institutions in Hong Kong, mainland China and overseas, including the National University of Singapore, University of Osaka, University of Melbourne, Purdue University, Hebrew University of Jerusalem, University of Hong Kong, HK Polytechnic University, Fudan University, Peking University, Capital University of Medical Sciences, Shanghai Institute of Medical Genetics, and others. Prof Pang is also member, Ophthalmology Basic Research Advancement Committee, Chinese Ophthalmological Society, Chinese Medical Association.
Professor Pang’s research interests include genomic and gene studies of glaucoma (POAG and PACG), age-related macular degeneration, polypoidal choridal vasculopathy, central serous chorioretinopathy, diabetic retinopathy, diabetic macular edema, retinitis pigmentosa, retinoblastoma, uveitis, myopia, congenital cataracts, keratoconus and corneal dystrophies. He also works on therapeutic effects of green tea extract, catechins, small herbal molecules and GHRHR (Growth hormone related hormone receptor) agonists and antagonists against ocular complications, especially inflammation, in cellular and animal studies. His other research area is on the biological roles played by induced pluripotent stem cells (iPSCs), periodontal ligament-derived stem cells (PDLSCs) and adipose-derived stem cells (ADSCs) in retinal ganglion cells survival and axon regeneration.
Professor Pang has published more than 410 papers in international peer-reviewed journals and 16 book chapters.
Professor Daniel Pauleikhoff
Professor Pauleikhoff was awarded his medical degree from the University of Münster, Germany, in 1983, and became a research associate at the Department of Ophthalmology at the University of Duisburg-Essen, Germany. He then specialized in retinal diseases and completed his residency in 1988. Afterwards, he started an 18-month fellowship in medical retina with Professor Alan C. Bird and Professor John Marshall at the University College London Institute of Ophthalmology/Moorfields Eye Hospital, in London, UK.
After his return to the University of Duisburg-Essen in 1989, Professor Pauleikhoff was appointed Senior Physician in the Department for Posterior Segment Disease. In 1993, he was appointed Senior Consultant of Ophthalmology at the Department of Ophthalmology, St. Franziskus-Hospital Münster, and continued as Professor of Ophthalmology at the University of Duisburg-Essen - positions that he continues to hold today. In 2010, he was awarded a further honorary professorship at Moorfields Eye Hospital.
Professor Pauleikhoff’s main research activities focus on the pathogenesis, phenotyping and treatment of AMD. He is principal investigator for various interventional clinical trials in AMD, diabetic retinopathy and retinal vein occlusion, and has received many scientific grants for basic science and clinical investigations. He serves on the editorial boards of several scientific ophthalmological journals and is an elected board member of the German Ophthalmological Society. He was elected President of the German Retina Society for the period 2012–2016 and re-elected as president in 2016 for another 4-year term, having served on the board of this society as a Vice-President for the previous 4 years. Professor Pauleikhoff has authored 180 publications in peer-reviewed journals, is Editor/Co-editor on several books on macular diseases, and has delivered several honorary lectures.
Professor Francesco Bandello
Professor Bandello is Full Professor and Chair at the Department of Ophthalmology at Vita-Salute San Raffaele University in Milan, Italy. Professor Bandello is a former President of EURETINA, Vice-President of Academia Ophthalmologica Europea, and a board member of EuroLam Retina.
Professor Bandello is Co-editor of the European Journal of Ophthalmology and former board member of both the Club Jules Gonin and the Macula Society. He is a member of the executive board of the European School for Advanced Studies in Ophthalmology Foundation, the Academia Ophthalmologica Internationalis, and the Accademia Nazionale di Medicina. Professor Bandello has co-authored nine books and serves as a peer reviewer for grant applications for the National Eye Institute. He has authored or co-authored over 300 articles, and he served as the principal investigator in several multicentre clinical trials, mainly concerning retinal diseases.
Professor Francine Behar-Cohen
Professor Behar-Cohen is a Professor of Ophthalmology and a vitreoretinal surgeon at Assistance Publique – Hôpitaux de Paris in France. Previously, she was Medical Director of the Jules Gonin Eye Hospital in Lausanne, Switzerland, and a Full Professor at the University of Lausanne and the Paris Descartes University.
Professor Behar-Cohen is Director of the ‘Physiopathology of ocular diseases: Therapeutic innovations’ team at the French National Institute of Health and Medical Research in the Cordeliers Research Centre in Paris. She is also the founder of start-up companies Optis France (now EyeGate Pharma) and Eyevensys S.A.S. (for which she serves as Scientific Advisor).
Professor Behar-Cohen has received awards for her research, including the Research Prize of the French Society of Ophthalmology, and is a member of numerous societies and scientific commissions. She is a member of the editorial board of Molecular Vision, the Journal of Ocular Pharmacology and Therapeutics, Translational Vision Science and Technology, and Progress in Retinal and Eye Research. She has published more than 190 articles and a dozen books or book chapters.
Professor Masahito Ohji
Professor Ohji is Chair of the Department of Ophthalmology at Shiga University of Medical Science in Otsu, Japan. He graduated from Osaka University Medical School, Suita, Japan, in 1983, and had become Assistant Professor of the Department of Ophthalmology by 1993. Professor Ohji has been on the editorial board for a range of journals and is Co-editor of Graefe's Archive for Clinical and Experimental Ophthalmology. He is also a board of trustees of the Japanese Ophthalmological Society and is an executive director of both and the Japanese Retina and Vitreous Society and the Japanese Society for Ocular Circulation, and is an executive committee member of the Club Jules Gonin.
Professor Ohji has produced more than 200 scientific publications and has co-authored many chapters in ophthalmology textbooks. His research interests include retinal and vitreous biology.
Dr Ohji’s institution: https://www.shiga-med.ac.jp/en
Professor Quan Dong Nguyen
Professor Nguyen is currently a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine, California, USA.
Professor Nguyen received his bachelor’s and master’s degrees simultaneously in molecular biophysics and biochemistry from Yale University, Connecticut. Subsequently, Professor Nguyen earned his medical degree as a Franklin Scholar at the University of Pennsylvania School of Medicine in Philadelphia. In addition, Professor Nguyen has completed an internship in Internal Medicine at the Massachusetts General Hospital, Harvard Medical School, Massachusetts; a residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts; as well as fellowships in immunology and uveitis at the Massachusetts Eye and Ear Infirmary; ocular immunology at the Johns Hopkins Wilmer Eye Institute in Baltimore, Maryland; and medical and surgical retina at the Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary.
Professor Nguyen has previously been on the faculty at the Wilmer Eye Institute of the Johns Hopkins Medical Institutions as Assistant Professor, before becoming Associate Professor of Ophthalmology, and then Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chair of the Department of Ophthalmology, and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, as well as Assistant Dean for Translational Research, at the University of Nebraska Medical Centre. In 2017, Professor Nguyen joined the faculty at the Byers Eye Institute at the Stanford University School of Medicine.
Professor Nguyen serves as principal investigator on multiple clinical trials investigating macular oedema, neovascular AMD, and ocular inflammatory and uveitic diseases. His team is known for its innovative work in early proof-of-concept clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Professor Nguyen and his team were among the first investigators in the world to evaluate aflibercept for neovascular AMD and diabetic macular oedema (DME), and ranibizumab for DME.
Professor Nguyen chaired the US multicentre READ-2, READ-3, and iDEAL studies, evaluating the potential role of vascular endothelial growth factor (VEGF) antagonists through different pathways for DME, and he led the SAVE, SAVE-2, and STOP-UVEITIS studies, evaluating the role of new pharmacological agents in uveitis and ocular inflammatory diseases.
With a prolific career that has seen him author numerous manuscripts, Professor Nguyen serves on the Editorial Board of several journals, including the Journal of Ophthalmic Inflammation and Infection and Ophthalmic Surgery, Lasers, and Imaging Retina, among others. Furthermore, since its launch in the fall of 2015, Professor Nguyen has been the Inaugural Editor-in-Chief of the American Journal of Ophthalmology Case Reports.
Professor Nguyen’s work has led to him being elected to many prestigious national and international medical associations; most notably, he was recently elected as Chair of the Board of Directors of the Vietnamese American Medical Association (VAMA) and General Secretary of the International Ocular Inflammation Society.
Professor Nguyen is co-chair of the GRAC, alongside Dr Jennifer Arnold.